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Spinal cord injury (SCI) is a major cause of morbidity, and leads to significant physical, 
emotional and financial burdens for individuals and their families. There is no known 
cure to date and current treatment options are limited. A cascade of secondary tissue 
damage starts within minutes to hours of an initial traumatic SCI, worsening the cellular 
and functional recovery. The time course of secondary damage does, however, offer a 
potential window of opportunity for intervention. It may be possible to administer new 
therapeutics during this early period, to prevent the extensive spread of damage to 
adjacent healthy tissue.  
Over the past two decades, regulation of Connexin43 hemichannels has provided a 
novel avenue of research into limiting the secondary damage of SCI. Peptide5, a 
Connexin43 mimetic peptide, is a promising candidate that shows efficacy in blocking 
Connexin43 hemichannels, thus preventing the propagation of neurotoxic molecules 
from the injured cells to the nearby intact tissue in a number of neural injury models. 
Peptide5, in particular, has been shown to reduce secondary tissue damage and to 
improve functional recovery when delivered directly to the site of SCI. However, direct 
application of peptides to a spinal cord lesion is likely to be impractical in a clinical 
setting, and might result in delays to the initiation of treatment. Therefore, the current 
research project aims to demonstrate that the systemic administration of Peptide5 is a 
clinically relevant treatment option for traumatic SCI by (1) optimising the systemic 
administration protocol of Peptide5; (2) investigating the cellular and function 
improvements in SCI rats from the Peptide5 systemic administration; and (3) examining 
the safety profile of Peptide5 systemic administration protocol. 
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Mass spectrometry and electrophoresis were used to determine the in vitro degradation 
curves in normal rat and human sera. A rat model of contusive SCI was then employed 
to optimise the dosing regimen and investigate the efficacy of Peptide5 in limiting 
secondary tissue damage and improving functional recovery. The lesion size was 
assessed on Haematoxylin and Eosin stained histological sections, and fluorescent 
immunohistochemistry was utilised to examine the Connexin43 protein and 
hemichannels, as well as cellular responses. The behavioural improvements were 
evaluated from motor (open field and error ladder tests) and sensory (mechanical pain 
hypersensitivity) functions. Fluorescent-labelled Peptide5 was delivered to the SCI and 
normal rats systemically in order to determine the in vivo distribution. 
It was found that the in vitro half-life of Peptide5 was 2 hours in normal rat serum and 
that the most effective dosing regimen was three injections of Peptide5 at 0 (10 mg/kg), 
2 (5 mg/kg) and 4 (2.5 mg/kg) hours post-injury. Compared with controls, Peptide5 
treated rats showed significant improvements in hind limb locomotor function and 
mechanical pain hypersensitivity. Peptide5 treatment led to a reduction in Connexin43 
protein level, hemichannel opening, lesion size, astrogliosis, macrophage and/or 
microglial activation, and neuronal cell death. There was no evidence to suggest that 
Peptide5 had any adverse systemic effects in normal and SCI animals, or influenced 
other connexins in the spinal tissue. 
The current research project demonstrated that systemic administration of Peptide5 is a 
feasible, neuroprotective and safe treatment option for ameliorating secondary damage 
and improving functional recovery in a contusive SCI model of rats. These findings 
provide strong support for the clinical use of Peptide5 in the near future.
